Honored for excellence and innovation in cardiovascular health diagnostics for Viz HCM module
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success.
“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “HCM is an underdiagnosed condition that is the most commonly inherited cardiac disease, yet, unfortunately only 15% of these patients are diagnosed. The recognition of Viz HCM, which accelerates the patient identification and journey for this serious disease, validates our efforts to help clinicians to deliver faster and better care.”
Viz HCM uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from across a health system to identify suspected HCM cases, notify cardiology care teams and increase the likelihood that patients get the right follow-up and diagnosis. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb (NYSE:BMY), was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. Recent data, presented at the American College of Cardiology meeting, demonstrated that Viz HCM successfully helped identify 574 HCM patients in a single major academic hospital (Cleveland Clinic) in a 9 month period, highlighting Viz HCM’s ability for more effective disease detection.1
All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.
Winners were announced at the Edison Awards Gala on April 3, 2025 in Fort Myers, FL.
For more information on Viz HCM, please visit https://www.viz.ai/hypertrophic-cardiomyopathy.
1 Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2025.02.024
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!